STRYVE FOODS, INC. reported Fourth Quarter 2023 results: revenue $2.9 million.
“Net sales of $2.9 million, compared to $5.4 million in the year-ago quarter.”
Earnings Releases
Quarterly and annual results disclosed under 8-K Item 2.02.
Guardion Health Sciences, Inc. reported the year ended December 31, 2023 results: revenue $12,248,550, net income $158,033, EPS $0.12.
“31, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the year ended December 31, 2023 include the following: ● Total revenue was $12,248,550 for the year ended December 31, 2023, as compared to $11,049,772 for the year ended December 31, 2022, an increase of $1,198,778, or 10.8%. The Viactiv ® product line generated”
Ondas Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $15.7 million.
“2 ea020288601ex99-1_ondas.htm PRESS RELEASE, DATED APRIL 1, 2024 Exhibit 99.1 Ondas Holdings Reports Fourth Quarter and Full Year 2023 Financial Results Record 2023 revenues of $15.7 million, an increase of 638% over 2022, driven by commercial adoption of the Optimus System and record product revenues at Ondas Networks Q4 2023 revenues were $5.0 million, a”
Polar Power, Inc. reported three months and full year ended December 31, 2023 results: revenue $15.3 million, net income Net loss was $6.5 million, EPS $(0.49) per basic and diluted share.
“solar hybrid DC power solutions, reports its financial results for the three months and full year ended December 31, 2023. 2023 Financial Highlights ● Net sales in 2023 were $15.3 million compared to $16.1 million in 2022 ● Gross profit for 2023 was $0.7 million compared to $2.1 million in 2022 ● Operating expenses for 2023 were $6.7 million compared to $7.7”
LM FUNDING AMERICA, INC. reported the year ended December 31, 2023 results: revenue approximately $13.0 million, net income approximately $15.9 million.
“Total revenue for the year ended December 31, 2023, was approximately $13.0 million, an increase of $11.3 million, or more than 648%, from $1.7 million in 2022.”
LM FUNDING AMERICA, INC. reported the fourth quarter ended December 31, 2023 results: revenue approximately $4.1 million, net income approximately $1.6 million.
“Total revenue for the fourth quarter ended December 31, 2023, was approximately $4.1 million, an increase of $2.9 million, or approximately 262%, compared to $1.1 million for the fourth quarter of 2022.”
EVOME MEDICAL TECHNOLOGIES INC. reported preliminary financial results for the year ended December 31, 2023.
“On April 1, 2024, Evome Medical Technologies Inc. issued a press release containing certain preliminary annual financial results for the year ended December 31, 2023.”
AQUABOUNTY TECHNOLOGIES INC reported financial results for the fourth quarter and full year ended December 31, 2023.
“On April 1, 2024 AquaBounty Technologies, Inc. issued a press release regarding its financial and corporate updates for the quarter and year ended December 31, 2023.”
SKYX Platforms Corp. reported the Fourth Quarter and Fiscal Year ended December 31, 2023 results: revenue $58.8 million, net income net loss of $39.7 million, or $(0.45) per share, EPS $(0.45) per share.
“Revenue in 2023 increased to a record $58.8 million – including record fourth quarter sales of $22.2 million which were realized in the fourth quarter – including E-commerce sales, smart home products and advanced plug & play products”
American Strategic Investment Co. reported the quarter and year ended December 31, 2023 results: revenue $15.4 million, net income Net loss attributable to common stockholders was $73.9 million or $32.27 per share, EPS $(0.65) per share.
“York City, announced today its financial and operating results for the fourth quarter and year ended December 31, 2023. Fourth Quarter 2023 and Subsequent Events • Revenue was $15.4 million • Net loss attributable to common stockholders was $73.9 million or $32.27 per share including a non-cash impairment on an office property • Adjusted EBITDA of $3.4 million •”
NewtekOne, Inc. updated its the three months ended March 31, 2024 guidance (reaffirmed).
“On April 1, 2024 the Company issued a press release entitled, "NewtekOne Announces Loan Closings for the First Quarter 2024."”
NewtekOne, Inc. reported the twelve months ended December 31, 2023 results: EPS $1.89 per basic share and $1.88 per diluted share.
“Full Year 2023 Basic Earnings per Share of $1.89 and Diluted Earnings per Share of $1.88”
NewtekOne, Inc. reported the three months ended December 31, 2023 results: net income $10.8 million, EPS $0.43 per basic and diluted common share.
“Net income was $10.8 million, or $0.43 per basic and diluted common share, for the three months ended December 31, 2023”
FRACTYL HEALTH, INC. reported financial results for quarter and year ended December 31, 2023.
“On April 1, 2024, Fractyl Health, Inc. announced its financial results for the quarter and year ended December 31, 2023 and provided a corporate update.”
Vislink Technologies, Inc. reported the full year ended December 31, 2023 results: revenue $27.5 million, net income $(9.1) million, EPS $(3.83) per share.
“Full Year 2023 Financial Results ● Revenue was $27.5 million, compared to $28.1 million in 2022. The change in revenue was a result of product line streamlining efforts, which started in 2022, and the discontinuation of lower-margin, sub-scale product lines. ● Gross margin increased to 51%, up from 46% in 2022. The increase was due to the greater contribution of software and services to total revenue. ● Net loss attributable to common shareholders totaled $(9.1) million, or $(3.83) per share, an improvement compared to $(13.5) million, or $(5.81) per share, in 2022.”
Vislink Technologies, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $8.1 million, net income $(2.4) million, EPS $(0.99) per share.
“Fourth Quarter 2023 Financial Results ● Revenue increased to $8.1 million, compared to $7.4 million in the prior year period. ● Gross margin increased to 46%, up from 33% in the prior year period. The improvement in gross margin was due to the greater contribution of MilGov revenue and software and services to total revenue, partially offset by one-time manufacturing charges related to new products. ● Net loss attributable to common shareholders totaled $(2.4) million, or $(0.99) per share, an improvement compared to $(5.5) million, or $(2.36) per share, in the prior year period.”
Bright Mountain Media, Inc. reported the year ended December 31, 2023 results: revenue $44.5 million, net income $35.6 million.
“Revenue was $44.5 million, an increase of $25.0 million, or 128%, compared to $19.6 million for the same period of 2022”
Bright Mountain Media, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $15.1 million, net income $5.9 million.
“Revenue was $15.1 million, an increase of $10.0 million, or 193%, compared to $5.2 million for the same period of 2022”
Akari Therapeutics Plc reported the full year ended December 31, 2023 results: net income Net loss was approximately $10.0 million for the year ended December 31, 2023.
“Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights”
Beeline Holdings, Inc. reported fourth quarter and year end financial results for the period ended December 31, 2023 results: revenue $2.1 million, net income $2.1 million.
“record digital can printing results in the first quarter—we are off to a great start.” Financial Results Gross sales for the three months ending December 31, 2023 decreased to $2.1 million from $2.4 million for the three months ending December 31, 2022, as both mobile canning and spirits sales were down, offset by an increase in digital can printing. Year over year”
Acutus Medical, Inc. reported fiscal year ended December 31, 2023 results: net income Net loss on continuing operations on a GAAP basis was $11.9 million for the full year ended December 31, 2023 and net lo, EPS net loss per share was $0.41.
“On April 1, 2024, the Company issued a press release announcing its financial results for the fiscal year ended December 31, 2023.”
DecisionPoint Systems, Inc. reported FY 2023 (year ended December 31, 2023) results: revenue $115.6 million, net income $2.5 million, EPS $0.32.
“Full Year 2023 Highlights (versus 2022) ● Revenue increased 18.7% to $115.6 million; ● Gross Profit increased 24.8% to $28.8 million; Gross Margin increased 120 basis points to 24.9%; ● GAAP Operating Income increased 7.4% to $4.8 million; ● GAAP Net Income and diluted EPS decreased 20.1% and 21.3% to $2.5 million and $0.32, respectively;”
DecisionPoint Systems, Inc. reported Q4 2023 (three months ended December 31, 2023) results: revenue $30.5 million, net income -$0.3 million, EPS -$0.03.
“Fourth Quarter Highlights (2023 versus 2022) ● Revenue increased 24.8% to $30.5 million; ● Gross Profit increased 18.7% to $7.5 million; Gross Margin decreased 130 basis points to 24.6%; ● GAAP Operating Income increased 3.7% to $0.7 million; ● GAAP Net Loss and diluted Loss per Share (EPS) of ($0.3) million and ($0.03), respectively;”
IZEA Worldwide, Inc. reported the fiscal year ended December 31, 2023 results: revenue $36.2 million, net income loss of $7.3 million.
“FY 2023 Financial Summary Compared to FY 2022 • Total revenue decreased 12% to $36.2 million, compared to $41.1 million • Net loss was $7.3 million, compared to a net loss of $4.5 million”
IZEA Worldwide, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $8.9 million, net income loss of $1.5 million.
“Q4 2023 Financial Summary Compared to Q4 2022 • Total revenue increased 1.0% to $8.9 million, compared to $8.8 million • Total costs and expenses increased 8.5% to $11.1 million, compared to $10.2 million • Net loss was $1.5 million, compared to a net loss of $0.9 million”
ATOSSA THERAPEUTICS, INC. reported financial results for the year ended December 31, 2023.
“Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the forth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.”
Carisma Therapeutics Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“On April 1, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.”
NEXGEL, INC. reported the fourth quarter and year ended December 31, 2023 results: revenue $4.1 million, net income Net loss for the year ended December 31, 2023, was $3.2 million.
“NEXGEL Reports Full Year 2023 Revenue of $4.1 Million”
Tonix Pharmaceuticals Holding Corp. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On April 1, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2023.”
TREVENA INC reported full year ended December 31, 2023 results: net income $40.3 million, EPS $3.16 per share.
“For the full year ended December 31, 2023, net loss attributable to common stockholders was $40.3 million, or $3.16 per share, compared to $53.7 million, or $7.59 per share.”
TREVENA INC reported fourth quarter ended December 31, 2023 results: net income $16.5 million, EPS $1.06 per share.
“For the fourth quarter of 2023, the Company reported a net loss attributable to common stockholders of $16.5 million, or $1.06 per share, compared to $7.0 million, or $0.73 per share in the fourth quarter of 2022.”
Venus Concept Inc. reported three and twelve months ended December 31, 2023 results: revenue $18.1 million, net income GAAP net loss attributable to stockholders of $11.1 million.
“to 58% in the prior year period • Macroeconomic headwinds and accelerated restructuring in international markets resulted in softer-than-expected system sales; total revenue of $18.1 million, down $6.2 million, or 25%, year-over-year; up $0.5 million, or 3%, quarter-over-quarter • Operating expenses of $19.7 million, including approximately $0.3 million of costs”
Sunshine Biopharma Inc. reported the fiscal year ended December 31, 2023 results: revenue $ 24,092,787, net income $ 4,506,044, EPS negative $0.19 per share.
“The following are key items contained in the Company’s Income Statement included in the 2023 10-K: 2023 2022 Sales $ 24,092,787 $ 4,345,603 Gross Profit $ 8,339,171 $ 1,696,575 General & Administrative Expenses $ 13,124,470 $ 28,697,325 Goodwill impairment $ – $ 18,326,719 Net Loss $ 4,506,044 $ 26,744,440”
FlexShopper, Inc. reported year ended December 31, 2023 results: revenue $117.0 million, net income $8.3 million, EPS $(0.51) per diluted share.
“vs. Twelve Months Ended December 31, 2022: ● Total fundings increased 7.7% to $120.4 million from $111.8 million ● Total net lease and loan revenues and fees increased 3.4% to $117.0 million from $113.1 million ● Gross profit increased 47.4% to $54.7 million from $37.1 million ● Adjusted EBITDA 1 increased by $23.7 million to $23.2 million compared to ($0.5) million”
FlexShopper, Inc. reported quarter ended December 31, 2023 results: revenue $30.3 million, net income $(715) thousand, EPS $(0.03) per diluted share.
“Total net lease and loan revenues and fees increased 40.9% to $30.3 million from $21.5 million”
ProMIS Neurosciences Inc. reported the fiscal year ended December 31, 2023 results: net income $13.2 million.
“Net loss was $13.2 million for the full year ended December 31, 2023, compared to a net loss of $18.1 million for full year in 2022.”
OMEROS CORP reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, EPS net loss of $117.8 million, or $1.88 per share.
“Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, which include: ● Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter. ● For the year ended December 31, 2023, net loss was $117.8 million, or $1.88 per share, compared to net income of $47.4 million, or $0.76 per share, in the prior year.”
BATTALION OIL CORP reported the fourth quarter of 2023 results: revenue $47.2 million, net income $27.0 million, EPS $1.63 per share.
“Results of Operations Average daily net production and total operating revenue during the fourth quarter of 2023 were 12,022 Boe/d (46% oil) and $47.2 million, respectively, as compared to production and revenue of 15,696 Boe/d (51% oil) and $76.8 million, respectively, during the fourth quarter of 2022. The decrease in revenues in the fourth quarter of 2023 as compared to the fourth quarter of 2022 is attributable to an approximate 3,674 Boe/d decrease in average daily production and a $10.21 decrease in average realized prices (excluding the impact of hedges). Excluding the impact of hedges, Battalion realized 99.7% of the average NYMEX oil price during the fourth quarter of 2023. Realized hedge losses totaled approximately $3.0 million during the fourth quarter 2023. Lease operating and workover expense was $11.87 per Boe in the fourth quarter of 2023 versus $9.89 per Boe in the fourth quarter of 2022. The increase in lease operating and workover expense per Boe year-over-year is pr”
BRAINSTORM CELL THERAPEUTICS INC. reported the year ended December 31, 2023 results: net income $17.2 million, EPS $0.40.
“On April 1, 2024, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2023.”
YIELD10 BIOSCIENCE, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On April 1, 2024 , Yield10 Bioscience, Inc. issued a press release announcing the financial results for the quarter and fiscal year ended December 31, 2023.”
VirTra, Inc reported for the full year ended December 31, 2023 results: revenue $38.0 million, net income $8.4 million, EPS $0.77 per diluted share.
“in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 VirTra Reports Fourth Quarter and Full Year 2023 Financial Results Annual Revenue Grows to a Record $38.0 Million, Marking a 34% Increase Net Income Increases to $8.4 Million in 2023 CHANDLER, Ariz. — April 1, 2024 — VirTra, Inc . (Nasdaq: VTSI) (“VirTra”), a global provider of judgmental”
VirTra, Inc reported for the fourth quarter ended December 31, 2023 results: revenue $10.1 million, net income $2.8 million, EPS $0.25 per diluted share.
“December 31, 2023. The financial statements are available on VirTra’s website and here . Fourth Quarter 2023 Financial Summary: ● Total revenue increased 17% year-over-year to $10.1 million ● Gross profit increased 58% year-over-year to $8.4 million, or 83% of total revenue ● Net income increased by $1.4 million year-over-year to $2.8 million ● Adjusted EBITDA”
NATURAL GAS SERVICES GROUP INC reported financial results for the three months and full year ended December 31, 2023.
“Natural Gas Services Group, Inc. Reports Full Year and Fourth Quarter 2023 Earnings”
374Water Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $744,000.
“For the twelve month period ended December 31, 2023, the Company generated revenue of $744,000 which compares to $3,016,000 for the twelve months ending December 31, 2022, a 75% decrease.”
Creative Media & Community Trust Corp reported the three months and year ended December 31, 2023 results: net income Net loss attributable to common stockholders of $16.3 million, or $0.72 per diluted share, EPS $0.72 per diluted share.
“Creative Media & Community Trust Corporation Reports 2023 Fourth Quarter Results”
Accelerate Diagnostics, Inc reported financial results for the quarter and full-year ending December 31, 2023.
“On March 28, 2024, Accelerate Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full-year ending December 31, 2023”
ESCALADE INC reported financial results for fourth quarter and full year 2023.
“Escalade Reports Fourth Quarter and Full Year 2023 Results EVANSVILLE, IN, March 29, 2024”
TherapeuticsMD, Inc. reported the full year ended December 31, 2023 results: net income Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, EPS $(0.74) per basic and diluted common share.
“TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.”
Strong Global Entertainment, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $42.6 million for the year and ... $10.3 million for the quarter, net income $3.0 million.
“announced operating results for the fourth quarter and full year ended December 31, 2023. Operational Highlights - Fourth Quarter and Full Year 2023 ● Revenue increased 9.4% to $42.6 million for the year and decreased 2.1% to $10.3 million for the quarter. ○ Upgrades to laser projection continue to drive customer demand. ○ Services revenue grew 26.6% during the”
Getaround, Inc reported the year ended December 31, 2023 results: revenue $72.7 million, net income GAAP Net Loss of $113.9 million.
“focus on cost optimization measures. Throughout the year we also recognized significant benefits from the business restructuring announced in February 2023." ● Total Revenues of $72.7 million, an increase of 22% year-over-year ● Gross Booking Value of $204 million, an increase of 16% year-over-year ● Gross margin from Service revenue was 85%, consistent with the prior”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.